Maiwald Magazine

Press Articles

14 Jul 2025 - Pressebericht

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

Royalty Pharma plc and Revolution Medicines, Inc. have announced a strategic funding collaboration of up to $2 billion to support the global development and commercialization of Revolution’s RAS(ON) inhibitor portfolio, particularly the clinical advancement of lead candida...

14 Jul 2025 - Pressebericht

Eight Opponents Succeed in Revocation of Salix’s Rifaximin Patent at the EPO

In a significant development, the European Patent Office (EPO) has revoked Salix Pharmaceuticals’ European patent for the antibiotic rifaximin. In decision T 0162/22, the EPO Board of Appeal confirmed the revocation of European Patent EP 2 252 148 following the wit...

9 Jul 2025 - Pressebericht

EP 3 996 688 Maintained as Granted: Maiwald Successfully Defends Formulation Patent for Tepotinib

We are happy to report that we successfully defended Merck’s formulation patent EP 3 996 688 for c-Met inhibitor Tepotinib (TEPMETKO®) in opposition proceedings at the hearing on July 9, 2025. The patent is upheld as granted.

Maiwald in the press

18 Jul 2025 - Publikation

EU regulation on plants from new genomic techniques: green shoots of progress? ManagingIP 2025

In a specialist article, Kerstin Wolff analyzes the current state of EU regulation on new genomic techniques (NGTs). In February 2024, the European Parliament proposed exempti...

11 Jun 2025 - Publikation

Managing IP Awards interview: Maiwald
ManagingIP June 10, 2025

In their recent feature with Managing IP, senior representatives from Maiwald – Dr. Anja Fux, Dr. Derk Vos, Heike Roeder-Hitschke, Dr. Nils Braun and Martina Boidol...

30 Apr 2025 - Publikation

Safe Harbor Provision in European Patent LawThe Research & Bolar Exemptions, AIPLA Chemical Practice Chronicles Newsletter, Volume 13 Issue 1 2025

This article covers the most recent developments regarding the European Research Exemption, which permits the use of patented inventions for research purposes, as well as the ...

Events

Mon.

22 Sep 2025 |Upcoming|Externe Veranstaltungen

Maiwald at the Munich IP Forum 2025

On 22 and 23 September 2025, the Munich IP Forum will take place at the Rosewood Hotel in Munich – an international conference for decision-makers in the field of intellectual property. The event brings together representatives from leading companies in industries such as pharmaceuticals, biotechnology, automotive, telecommunications and electronics with IP experts from ...

Wed.

16 Jul 2025 |Past Event

Maiwald office trip 2025

This year’s firm outing took the entire Maiwald team to the Adventurecamp Schnitzmühle in Viechtach. Although the weather was somewhat unpredictable, it did nothing to dampen our spirits – quite the opposite: the day was filled with positive energy, exciting activities, and memorable moments. The program included:

Wed.

21 May 2025 |Past Event|Externe Veranstaltungen

C5’s 18th Annual Forum on “Pharma & Biotech Patent Litigation in Europe” in Amsterdam

We are pleased that Dr. Eva Susanne Ehlich was an expert at the 18th C5 Communications Forum on “Pharma & Biotech Patent Litigation in Europe” in Amsterdam. Eva gave a presentation on “Plausibility and Post-Publication Evidence in Inventi...

Tue.

20 May 2025 |Past Event|Vortag Live

Joint symposium with Oblon in Tokyo on May 20, 2025

The The Oblon and Maiwald firms were pleased to host a complimentary joint international symposium on: U.S. and European Patent Practice: Important Aspects for Practitioners At the 2025 joint symposium, selected current aspects of protecting innovations in the U.S. and Europe were examined, considering b...

All events

News and Releases

Maiwald Blog

Turn one into several – what Rule 80 EPC says about using several independent claims to defend one independent claim

EPO Board of Appeal 3.3.04 is setting the right standard for acknowledging novelty of non-medical use claims (T 1913/21)

EPO revokes Roche’s Patent on combination therapy of bevacizumab and paclitaxel for platinum-resistant ovarian cancer that was supported by results of Phase III AURELIA clinical trial

Press Articles

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

Eight Opponents Succeed in Revocation of Salix’s Rifaximin Patent at the EPO

EP 3 996 688 Maintained as Granted: Maiwald Successfully Defends Formulation Patent for Tepotinib

Staff News

Marvin Bäumel sworn in as German patent attorney

Maiwald appoints Alexander Feil, Dr. Johannes Scholz and Dr. Fabian Wiescher as Counsel

Maiwald congratulates Dr. Anna Closs on passing the exam

EU regulation on plants from new genomic techniques: green shoots of progress? ManagingIP 2025

Managing IP Awards interview: Maiwald
ManagingIP June 10, 2025

Safe Harbor Provision in European Patent LawThe Research & Bolar Exemptions, AIPLA Chemical Practice Chronicles Newsletter, Volume 13 Issue 1 2025

Awards

Maiwalds IP Stars & Notable Practitioners 2024 by Managing IP

2025 IP Stars Patent Rankings in the categories “Patent Prosecution” and “Patent Disputes” revealed

Dr. Marco Stief honoured as Thought Leader Germany, Lexology Index 2025

Events

Maiwald at the Munich IP Forum 2025

Maiwald office trip 2025

C5’s 18th Annual Forum on “Pharma & Biotech Patent Litigation in Europe” in Amsterdam

Joint symposium with Oblon in Tokyo on May 20, 2025